Product Description: LUT014 is a B-Raf inhibitor with an IC50 of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 [1].
Applications: COVID-19-immunoregulation
Formula: C27H19F3N8O
References: [1]Noa Shelach. Novel braf inhibitors and use there of for treatment of cutaneous reactions. WO2019026065A2.